A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Study of Amrbisentan in Subjects with Pulmonary Arterial Hypertension

Grants and Contracts Details

StatusFinished
Effective start/end date9/1/05 → 4/30/06

Funding

  • Myogen Inc: $3,150.00